{"filing":{"accession_number":"0001193125-26-425647","cik":"0002012593","ticker":"RAPP","company_name":"Rapport Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"d185134d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm"},"events":[{"id":36228,"run_id":33393,"accession_number":"0001193125-26-425647","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Rapport announced positive topline results from a Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with statistically significant improvements in YMRS and CGI-BP scores and a favorable safety profile. This clinical development milestone establishes proof-of-concept for the company's lead candidate and supports progression to Phase 3 trials expected in H2 2027.","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40565,"accession_number":"0001193125-26-425647","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rapport announced positive topline results from a Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with statistically significant improvements in YMRS and CGI-BP scores and a favorable safety profile. While this is clinical trial data rather than a traditional earnings release, it represents a material operational milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and regulatory pathway. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02 (Results of Operations), making it operational rather than a formal earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:07:56.631648+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40566,"accession_number":"0001193125-26-425647","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rapport announced positive Phase 2 trial results for RAP-219 in bipolar mania on October 20, 2026, meeting its primary endpoint with statistically significant placebo-adjusted improvement in YMRS scores (3.1 points, p=0.045) and demonstrating favorable tolerability. While this is a clinical development milestone rather than a financial earnings release, it represents a material operational event for a clinical-stage biotech company—establishing proof-of-concept for a lead candidate and supporting progression to Phase 3 trials expected in H2 2027. This is distinct from earnings_release (which typically reports financial results) and fits operational_other as a significant clinical/development milestone affecting investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:07:56.631648+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40565,"accession_number":"0001193125-26-425647","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rapport announced positive topline results from a Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with statistically significant improvements in YMRS and CGI-BP scores and a favorable safety profile. While this is clinical trial data rather than a traditional earnings release, it represents a material operational milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and regulatory pathway. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02 (Results of Operations), making it operational rather than a formal earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:07:56.631648+00:00","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-10-20"},{"id":40566,"accession_number":"0001193125-26-425647","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Rapport announced positive Phase 2 trial results for RAP-219 in bipolar mania on October 20, 2026, meeting its primary endpoint with statistically significant placebo-adjusted improvement in YMRS scores (3.1 points, p=0.045) and demonstrating favorable tolerability. While this is a clinical development milestone rather than a financial earnings release, it represents a material operational event for a clinical-stage biotech company—establishing proof-of-concept for a lead candidate and supporting progression to Phase 3 trials expected in H2 2027. This is distinct from earnings_release (which typically reports financial results) and fits operational_other as a significant clinical/development milestone affecting investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:07:56.631648+00:00","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-10-20"}]}